Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study
Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma.
PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
OBJECTIVES:
OUTLINE: Patients receive carboplatin IV over 1 hour on days 0, 21, and 63; cyclophosphamide IV over 1 hour on days 21 and 42; doxorubicin IV over 15-60 minutes on days 21 and 63; and etoposide IV over 2 hours on days 0-2, 42-44, and 63-65. Patients under 60 days of age also receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after the last chemotherapy administration and continuing until blood counts recover. Patients with favorable biology who do not achieve complete remission then undergo surgery to remove or debulk residual disease on day 84 or when blood counts recover. Patients with favorable biology who achieve partial response and surgery to the primary site is not deemed in the best interest of the patient may receive additional chemotherapy (as below) and delay surgery to the primary site after completion of chemotherapy.
Patients with unfavorable biology receive additional chemotherapy comprising cyclophosphamide IV over 1 hour on days 84, 105, and 147; etoposide IV over 2 hours on days 84-86 and 126-128; carboplatin IV over 1 hour on days 105 and 126; and doxorubicin IV over 15-60 minutes on days 105 and 147. Patients then undergo debulking surgery on day 168 or when blood counts recover.
Some patients may then undergo radiotherapy after surgery.
Patients are followed monthly for 6 months, every 2 months for 6 months, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
Histologically proven neuroblastoma or maturing ganglioneuroma that is judged to be intermediate risk by one of the following criteria:
International Neuroblastoma Staging System (INSS) stage III
INSS stage IV
INSS stage IVS
All patients must be registered on the companion neuroblastoma biology study (COG-ANBL00B1)
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Birmingham, Alabama 35233, United States
Tucson, Arizona 85724, United States
Little Rock, Arkansas 72205, United States
Loma Linda, California 92354, United States
Long Beach, California 90801-1428, United States
Los Angeles, California 90048, United States
Orange, California 92868, United States
Palo Alto, California 94304, United States
San Diego, California 92120, United States
Santa Clara, California 95051, United States
Travis Air Force Base, California 94535, United States
Farmington, Connecticut 06360-7106, United States
New Haven, Connecticut 06520-8064, United States
Washington D.C., District of Columbia 20007, United States
Atlanta, Georgia 30342, United States
Savannah, Georgia 31405, United States
Indianapolis, Indiana 46202-5225, United States
Lexington, Kentucky 40536-0284, United States
New Orleans, Louisiana 70112, United States
Baltimore, Maryland 21201-1595, United States
Baltimore, Maryland 21231-7223, United States
Boston, Massachusetts 02115, United States
Springfield, Massachusetts 01107, United States
Detroit, Michigan 48236, United States
Omaha, Nebraska 68198-2168, United States
Lebanon, New Hampshire 03756, United States
New Brunswick, New Jersey 08903, United States
Albuquerque, New Mexico 87131, United States
New York, New York 10032, United States
Rochester, New York 14642, United States
Stony Brook, New York 11794-8174, United States
The Bronx, New York 10461, United States
Chapel Hill, North Carolina 27599, United States
Charlotte, North Carolina 28232-2861, United States
Greenville, North Carolina 27858-4354, United States
Winston-Salem, North Carolina 27157-1081, United States
Fargo, North Dakota 58103-4940, United States
Cleveland, Ohio 44106-5065, United States
Oklahoma City, Oklahoma 73104, United States
Portland, Oregon 97227, United States
Portland, Oregon 97239-3098, United States
Charleston, South Carolina 29425-0721, United States
Sioux Falls, South Dakota 57117-5039, United States
Johnson City, Tennessee 37614-0622, United States
Dallas, Texas 75390-9063, United States
San Antonio, Texas 78229-3902, United States
Richmond, Virginia 23298-0121, United States
Roanoke, Virginia 24029, United States
Tacoma, Washington 98415-0299, United States
Charleston, West Virginia 25302, United States
Morgantown, West Virginia 26506-9300, United States
La Crosse, Wisconsin 54601, United States
St. John's, Newfoundland and Labrador A1B 3V6, Canada
San Juan, 00936-5067, Puerto Rico